This article first appeared on GuruFocus.

Diebold Nixdorf Inc (NYSE:DBD) is set to release its Q3 2025 earnings on Nov 5, 2025. The consensus estimate for Q3 2025 revenue is $937.70 million, and the earnings are expected to come in at $0.54 per share. The full year 2025's revenue is expected to be $3.83 billion and the earnings are expected to be $1.75 per share. More detailed estimate data can be found on the Forecast page.

Warning! GuruFocus has detected 5 Warning Sign with DBD.

Is DBD fairly valued? Test your thesis with our free DCF calculator.

Over the past 90 days, revenue estimates for Diebold Nixdorf Inc (NYSE:DBD) have increased from $3.79 billion to $3.83 billion for the full year 2025 and from $3.86 billion to $3.93 billion for 2026. Meanwhile, earnings estimates have declined from $2.07 per share to $1.75 per share for 2025 but have increased from $3.82 per share to $3.96 per share for 2026.

In the previous quarter ending 2025-06-30, Diebold Nixdorf Inc's (NYSE:DBD) actual revenue was $915.20 million, which beat analysts' revenue expectations of $879.54 million by 4.05%. Diebold Nixdorf Inc's (NYSE:DBD) actual earnings were $0.33 per share, which missed analysts' earnings expectations of $0.34 per share by -2.94%. After releasing the results, Diebold Nixdorf Inc (NYSE:DBD) was up by 5.78% in one day.

Based on the one-year price targets offered by 3 analysts, the average target price for Diebold Nixdorf Inc (NYSE:DBD) is $75.67 with a high estimate of $80.00 and a low estimate of $70.00. The average target implies an upside of 28.58% from the current price of $58.85.

Based on GuruFocus estimates, the estimated GF Value for Diebold Nixdorf Inc (NYSE:DBD) in one year is $0, suggesting a downside of -100% from the current price of $58.85.

Based on the consensus recommendation from 3 brokerage firms, Diebold Nixdorf Inc's (NYSE:DBD) average brokerage recommendation is currently 1.7, indicating an \\"Outperform\\" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.